Skip to main content
European Commission logo print header

NOVEL THERAPEUTIC NANOHYDROGEL FOR ACUTE AND CHRONIC PAIN TREATMENT TARGETED TO THE NERVES FASCIA

Project description

Novel nanomedical product for acute and chronic pain management

Spain-based company i+Med is developing a novel medical product for acute pain management and the prevention of chronic pain development. The new product will consist of a biocompatible and biodegradable injectable porous nanostructured hydrogel containing local anaesthetic drugs. The novel nanomedicine will provide fast and efficient functional recovery without causing addiction, and it can be easily administered by medical staff as a single injection. Importantly, it will dramatically reduce the possibility of chronic pain development, contributing to the reduction of lost productivity and medical and mental comorbidities. The EU-funded FasNaGel project will perform technical and economic feasibility studies and define a detailed business plan for the commercialisation of the product.

Objective

Worldwide chronic pain conditions are by far the greatest cause of disability. It has an enormous negative impact on quality of life and on personal and professional plane. Chronic pain is an important cause of depression, more sickness absences at work, productivity losses, unemployment, etc.). Chronic pain is one of the major reasons (30%) why people exit the labour market prematurely. 20% of current population in Europe suffers from chronic pain (102 mill.) and up to 50 % of that pain comes from wrongly treated acute post-operative pain. The total direct and indirect healthcare costs for chronic pain disorders in Member States have an EU average of 2.4 % of GDP and a cost of 271 billion euros per year. When acute pain is not properly treated in the first few days, it can become chronic. About 40-60% of patients report pain chronification after surgery. Current medicines do not prevent chronic pain from the start and have side effects. “Fast track” approaches have started to take the lead in pain management policies. Based on these approaches I +Med´s team works since 2014 in the development of FasNaGel, a new nanomedicinal product, unique in the world. It consists of a biocompatible and biodegradable injectable carrier, made of porous nanostructured hyaluronic acid hydrogel containing a non-steroidal anti-inflammatory drug that i) efficiently, provides a 100% of functional recovery after surgery in one third of the time, ii) is easy-to-use by medical staff, and the most important iii) increases by 80% the treatment effectiveness. FasNaGel will reduce the overall treatment costs in Europe, deducting indirect costs coming from acute pain up to €149 billion. The objective of this proposal is to be able to perform a thorough feasibility study for the validation of the production and commercialization of this novel product. FasNaGel marketing will have a huge of a SME such as i+Med, who estimates to multiply the team size by 8 in 7 years.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Coordinator

I+MED S COOP
Net EU contribution
€ 50 000,00
Address
CALLE ALBERT EINSTEIN 15
01510 Vitoria-Gasteiz
Spain

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Noreste País Vasco Araba/Álava
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 71 429,00